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1.2 Summary
Screening Íor Down's syndrome has been in practice since it became possible to diag-
nose this chromosomal def'cct prenatally. Until 1984, scrcening was based pr,rrely on
maternal age and prcvious history. Since 1984. the options available to screcn for
Down's syndrome have incrcased considerably and research has been aimcd at opti-
mising the screcning process.
Optimising a screening process involves increasing the sensitivity and specificity so
that as many as possible oÍ'the afÍ-ected individuals are identif ied (in this case, pregnant
women canying Íetuses affbcted by Down's syndrome) with as few as possible
"r' lomal" pregnancics bcing labclled as "increased risk". Scrcening always requires
further tests to verify its results. Should a scrcening process identify all the affected
individuals and none of the unaff-ected (ie lA}o/a scnsitivity and 100% specificity), then
it would be considered a diagnostic test. By definit ion, screening wil l never achieve the
same detection eff iciency as a diagnostic test, and as such, a comparison between the
two modalit ies is inappropriate.
Over the last 12 ycars, therc has been a constant drive to optimise Down's syndrome
screening . In this thesis. several ways of irnproving Down's syndrome screening have
been investigated.
The group of women ovcr 35 years of age are considered at high risk of having a Íetus
with Down's syndrome according to the or ig inal  (pre-1984) screening cr i ter ia.  In
countries where antenatal testing for Down's syndrome was offered, all the women in
this group were considered "scresn-positive" and were offered an invasive diagnostic
test. Although screening alternatives are now available, most countries sti l l  offer
invasive tests to this group of older women. Howcver, many of these wolnen arc
hesitant about undergoing invasive antenatal diagnostic testing because of the risk of
fetal loss caused by the test itself. Many of these women have olten endurcd prolon-
ged inferti l i ty, or consider this a "last chance" pregnancy. They are looking for ways
to minimise their need for an invasive tcst, whilst not losing too much in detection effi-
ciency.
The currently uscd second-trimestcr maternal serum-screening protocol (in this
thesis, a combination of maternal age, alpha-Í-etoprotein (AFP) and total human chorio-
nic gonadotropin (hCG) cstimations) was able to do this. Only 28%, of women aged 36
years or older were screcn-positive and all the í-ctuses with Down's syndrorne were in
this screen-positive groLrp. Largcr studies clsewherc have also conflrmed that, with a
dramatic reduction in thc number of women needing an invasivc test. more than 887o
of fetuses with Down's syndrome can be dctectcd.
Women pregnant after rru vitro l-ertllisation (IVF) also bclong to a special group. They
are oftcn older, and becoming pregnant has been more diff icult than for many other
women. As such, these women are also quite reticent about undergoing a diagnostic
pregnant through IVF are screen positive than cxpected using the existing second tri-
mester screening programme, biochemical screening is sti l l  superior to screening
with age alone.
Why women, pregnant as a result of IVF, have diflerent biochemical parameters
than those spontaneously pregnant is not clear. This provides an interesting field for
further research.
Many women and their pregnancy care-givers consider an earlier screening test. an
advantage as it would provide earlier rcassurance (for the majority) and an earlier and
medically safer termination of pregnancy if desired, should the f.etus be shown to have
Down's syndrome.
The move to bring serum screening into the first trimester of pregnancy has not been
as rapid as was originally expected. In the multicentre trial oÍ which we were part,
biochemical screening (using free-/3hCG and pregnancy associated plasma protein-A
(PAPP-A)) has been shown to potentially be able to detect 630/o of fetuscs with
Down's syndrome for a screen-positive rate of 5.5Vo. Howcver, our own study into
biochemical markers highlighted one of t lre continuing problems in Ílrst-trimester
screening. What is considered to be one of the best biochemical markers (PAPP-A)
has sti l l  not becorne a reliable, commercially-available assay. Until this happens, the
introduction of f irst-trirnester biochemical scrum screening wil l need to be delayed
unless a lesser efficiency in the programme is acceptable and only age and ïree-J3hCG
are used as parameters.
Other potential biochemical markers have been studied in this thesis, but have not
shown the detection efficiency required to optimise first-trimester serum screening.
Schwangerschafts Protein-1 (SP1) levels discriminate between pregnancies car-
rying a Down syndrome fetus and those without. However, freelhCG discriminates
better, so adding SP1 to the screening protocol would not improve screening efïïciency.
Urinary l3-core hCG, which may well improve second-trimester serum screening,
has been shown in this thesis not to be able to differentiate between Down's syndrome
and chromosomally normal fetuses in the first trimester of pregnancy.
Ultrasound (US), using a nuchal translucency (NT) measurement, has been promoted
as a superior metl-rod of screening tor Down's syndrome in the first trimester, with
detection rates of greater than 80 per cent for a less than 5 per cent screen-positive
rate. Our study showed that US screening was not effective if performed on all
women presenting for ultrasounds in the first trimester of pregnancy. Prior to l0
weeks' gestation, the NT could only be measured in 45 per cent of fetuses; this would
have necessitated a second ultrasound for more than halI of the womcn. Perlorming
the measurements routincly in first-trimester scans would add more than three
minutes to the US scan-tirne in many women. This would make it impractical in a


























































group of women having an US fbr other rcasons neglects the need fbr informed
consent. Unless women are aware of what is being screened for, and the implications
of a screen-positive result (i.e. the need to undergo an invasive diagnostic test) then
this extra measurcment should not be made. A thorough explanation and time to
consider the options are required betore this test is performed.
Finally, womcn's oprnions of moving Down syndrome screening from the second to
the flrst trimestcr were assessed, to see if the potcntial users of such a service consi-
dered it an advantage. Our study sLlggests that wornen already making usc oÍ-the
second-trimester programme would also use Í ' irst trimester screening. Those who had
consciously decided against second-trimester serum screening would also decline it
in the flrst-trimester. Older women, who were being offered an invasive first trimester
antenatal diagnostic test because of their age alone would, in many cases, welcome
the availabil ity o1'another Íorm of screening on which to base their decision.
Any form of screening in the first trimester would always need to take into account
that up to 50 per cent of Down syndrome fetuses wil l suff 'er spontaneous demise
between the time of the test and term.
Serum screening for Down's syndrome in the second trimester is a Íact of l i fè in
many countries and this thesis i l lustrates some of the eÍ'forts that have been made to
optimise this form of screening.
BeÍore first-trimester scrcening is implemented (be it biochemical- and/or ultra-
sound-based), large prospective studies on low-risk populations are needed to assess
whether this is truly an optimisation of screening in both technical and human terms.
